PROSTATE CANCER PROGRAM OVERVIEW

MSK’s urologic cancer program is recognized as one of the world’s finest, ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:
• safer and more precise treatments
• the benefit of seeing several dedicated prostate cancer specialists on one day, at one location
• an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
• access to innovative clinical trials of therapies, surgical and radiation therapy techniques, and advanced technologies not available at other hospitals
• genomic sequencing for all patients to look for actionable mutations

LOCATIONS

Many of our specialists are centrally located at our Manhattan location. We also have regional outpatient locations in:
• MSK Basking Ridge, New Jersey
• MSK Bergen, New Jersey
• MSK Monmouth, New Jersey
• MSK Commack, New York
• MSK Rockville Centre, New York
• MSK Westchester, New York

Our Team Leaders

James A. Eastham, MD, FACS
Chief, Urology Service; Peter T. Scardino Chair in Oncology

Howard I. Scher, MD
Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; D. Wayne Calloway Chair in Urologic Oncology

Michael J. Zelefsky, MD
Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

Peter T. Scardino, MD, FACS
David H. Koch Chair

Philip Kantoff, MD
Chair, Department of Medicine; George J. Bosl Chair

Vincent P. Laudone, MD
Chief of Surgery, Josie Robertson Surgery Center

Victor E. Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

Brett S. Carver, MD
Surgeon

Behfar Ehdaie, MD, MPH
Surgeon

REFER A PATIENT

Contact the Physician Access Service directly at

800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

Sign up for OncoNotes, MSK’s clinical updates newsletter.

Go to MSKCC.org, click on the For Health Professionals section, and choose “Sign Up for Our E-newsletter.”

Prostate Cancer Program

James A. Eastham, MD, FACS
Chief, Urology Service; Peter T. Scardino Chair in Oncology

Howard I. Scher, MD
Co-Chair, Center for Mechanism Based Therapy; Head of the Biomarker Development Initiative; D. Wayne Calloway Chair in Urologic Oncology

Michael J. Zelefsky, MD
Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

Peter T. Scardino, MD, FACS
David H. Koch Chair

Philip Kantoff, MD
Chair, Department of Medicine; George J. Bosl Chair

Vincent P. Laudone, MD
Chief of Surgery, Josie Robertson Surgery Center

Victor E. Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

Brett S. Carver, MD
Surgeon

Behfar Ehdaie, MD, MPH
Surgeon

July 2018
**WHY CHOOSE MSK FOR PROSTATE CANCER CARE?**

**Expertise**

- MSK prostate cancer experts have led all the drug discoveries that underpin clinical advances in prostate cancer treatment. Our expertise gives us an edge anticipating side effects, response rates, and drug resistance at the earliest stages.
- Our researchers developed the 4Kscore test that identifies men with an elevated PSA score who have a low risk of harboring a high-grade prostate cancer, enabling them to safely postpone or avoid a biopsy.
- Whether employing robotic or open radical prostatectomy, our surgeons operate with precision to preserve erectile tissue and continence.

**Leadership**

- We provide one of the largest prostate cancer programs in the country, performing more than 800 surgeries per year for new cancers, including patients who are not considered to be surgical candidates elsewhere.
- MSK founded and coordinates the Prostate Cancer Clinical Trials Consortium, a 13-member, multi-institutional research organization collaborating on over 140 clinical trials seeking to translate new drug discoveries to improved standards of care.
- MSK leads the National Cancer Institute’s Specialized Program of Research Excellence (SPORE) for prostate cancer, focused on defining the mechanisms of disease, developing validated assays and biomarkers for clinical trials, and demonstrating better outcomes for patients.
- We have over 47 prostate cancer clinical trials underway for a range of targeted therapies, immunotherapies, and novel surgical approaches.

**Advanced Technologies**

- We pioneered stereotactic hypofractionated accelerated radiation to the prostate, or SHARP, to safely and effectively deliver powerful doses of radiation directly to a person’s tumor with incredible precision.
- For most patients, we use the latest robotic surgical techniques, resulting in lower blood loss, decreased postoperative pain, shorter hospital stays, and faster recovery times than open surgery.
- We routinely utilize MSK-IMPACT™, a genome sequencing test developed at MSK, that quickly determines if tumors have actionable mutations using available targeted therapies or if patients may benefit from clinical trials.
- We have over 47 prostate cancer clinical trials underway for a range of targeted therapies, immunotherapies, and novel surgical approaches.

**By the Numbers**

- **10** prostate surgeons
- **9** radiation oncologists
- **17** urologic medical oncologists
- **7** locations
- **828** prostatectomies performed in 2017